Abstract
Classical Hodgkin lymphoma (cHL) is now recognized as a B-cell-derived lymphoma which is characterized by only about 1% malignant pathognomonic Hodgkin and Reed-Sternberg (HRS) cells and an abundant infiltrate of reactive bystander cells. HRS cells are unique with respect to their lost B-cell-specific gene expression pattern and recurrent genetic lesions. Aberrant activity of Notch signaling, a highly conserved developmental pathway, acts as a negative regulator of the B cell program in HRS cells and thereby contributes to their reprogramming. Another striking feature and the major pathogenetic mechanism in HRS cells is constitutive NF-κB activation. A number of aberrations that contribute to canonical NF-κB activity in HRS cells have been described such as genetic lesions, deregulated receptor signaling and Epstein-Barr virus (EBV) infection. The importance of Notch and NF-κB signaling for cHL pathogenesis, their potential cross-talk and implications for future therapeutic applications are being discussed.
Keywords: Notch, NF-κB, Hodgkin lymphoma, B cell lymphoma, Hodgkin/Reed-Sternberg cells, gene transcription, mutations, immunoprecipitation, inflammatory cells, cytokine, helix-loop-helix proteins, Epstein-Barr virus, Multiple Myeloma, B-chronic lymphocytic leukemia, tumor suppressor gene
Current Molecular Medicine
Title: Notch and NF-κB Signaling Pathways in the Biology of Classical Hodgkin Lymphoma
Volume: 11 Issue: 3
Author(s): R. Schwarzer and F. Jundt
Affiliation:
Keywords: Notch, NF-κB, Hodgkin lymphoma, B cell lymphoma, Hodgkin/Reed-Sternberg cells, gene transcription, mutations, immunoprecipitation, inflammatory cells, cytokine, helix-loop-helix proteins, Epstein-Barr virus, Multiple Myeloma, B-chronic lymphocytic leukemia, tumor suppressor gene
Abstract: Classical Hodgkin lymphoma (cHL) is now recognized as a B-cell-derived lymphoma which is characterized by only about 1% malignant pathognomonic Hodgkin and Reed-Sternberg (HRS) cells and an abundant infiltrate of reactive bystander cells. HRS cells are unique with respect to their lost B-cell-specific gene expression pattern and recurrent genetic lesions. Aberrant activity of Notch signaling, a highly conserved developmental pathway, acts as a negative regulator of the B cell program in HRS cells and thereby contributes to their reprogramming. Another striking feature and the major pathogenetic mechanism in HRS cells is constitutive NF-κB activation. A number of aberrations that contribute to canonical NF-κB activity in HRS cells have been described such as genetic lesions, deregulated receptor signaling and Epstein-Barr virus (EBV) infection. The importance of Notch and NF-κB signaling for cHL pathogenesis, their potential cross-talk and implications for future therapeutic applications are being discussed.
Export Options
About this article
Cite this article as:
Schwarzer R. and Jundt F., Notch and NF-κB Signaling Pathways in the Biology of Classical Hodgkin Lymphoma, Current Molecular Medicine 2011; 11 (3) . https://dx.doi.org/10.2174/156652411795243423
DOI https://dx.doi.org/10.2174/156652411795243423 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
On The Edge of Validation – Cancer Protease Fibroblast Activation Protein
Mini-Reviews in Medicinal Chemistry Identification of Novel Inhibitors for Disrupting EZH2-EED Interactions Involved in Cancer Epigenetics: An In-Silico Approach
Current Proteomics Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets Pharmacogenetics of Therapy in Inflammatory Bowel Disease Patients
Current Pharmacogenomics Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy Molecular Biology of the Enzymes that Degrade Endocannabinoids
Current Drug Targets - CNS & Neurological Disorders Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry The Return of the INGs, Histone Mark Sensors and Phospholipid Signaling Effectors
Current Drug Targets Precision Mechanics with Multifunctional Tools: How HnRNP K and HnRNPs E1/E2 Contribute to Post-Transcriptional Control of Gene Expression in Hematopoiesis
Current Protein & Peptide Science Understanding Autophagy in Cell Death Control
Current Pharmaceutical Design Mesenchymal Stem Cell as a Potential Therapeutic for Inflammatory Bowel Disease- Myth or Reality?
Current Stem Cell Research & Therapy Preface (Hot Topic: Bioactive Peptides from Food Proteins Executive Editor: Antonio Pellegrini )
Current Pharmaceutical Design Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals 3D-QSAR, Molecular Docking and Molecular Dynamics Studies of 2,4- Diarylaminopyrimidine Analogues (DAAP Analogues) as Potent ALK Inhibitors
Letters in Drug Design & Discovery Diketo Acids Derivatives as Integrase Inhibitors: The War Against the Acquired Immunodeficiency Syndrome
Recent Patents on Anti-Infective Drug Discovery Genomic and Cellular Pathology of Lung Cancer
Current Respiratory Medicine Reviews Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Interactions of Liposomes with Cells In Vitro and In Vivo: Opsonins and Receptors
Current Drug Metabolism